PTGS2 and type 1 diabetes mellitus: Therefore, the COX2 inhibitors are promising candidates for treating diabetes due to their ability to block prostaglandins (PGs) formation in monocytes and prevent antigen-presenting cell dysfunction, both of which could predispose a person to autoimmunity and IDDM (Fig 3).